Business Wire · AZN · October 24, 2026

Perioperative IMFINZI® (durvalumab) plus neoadjuvant enfortumab vedotin reduced risk of recurrence by 49% and risk of death by 42% in muscle-invasive bladder cancer

Stocks To Buy Now app

Get the app for more

Explore stock news, insights and company research.

Get the app →
Source: Business Wire ↗